Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Comparison between the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and their combination on mortality in maintenance dialysis patients: a systematic review and meta-analysis.International urology and nephrology · 2025
   Pooled it
2. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.Drugs · 2021
   Article
3. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Pharmacological research · 2017
   Review
4. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2016
   Review
5. The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Journal of clinical hypertension (Greenwich, Conn.) · 2016
   Observational
6. Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013
   Article
7. RAAS inhibition and mortality in hypertension.Global cardiology science & practice · 2013
   Review

Corrections and comments

• Comment on
  Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as